Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said.

The regulator approved the drug for moderate to severe obstructive sleep apnea in adults with obesity, the company said. "Too ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking it the first ...

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 471.82% and ...

Tirzepatide includes blockbuster injected GLP-1 medications Mounjaro (for diabetes) and Zepbound (for weight loss).

The FDA has declared the end of the two-year shortages of Eli Lilly's Mounjaro and Zepbound — used to treat diabetes and weight loss, respectively — and has reaffirmed its decision to halt the ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of ...

The FDA declared a shortage of popular weight-loss and diabetes drugs. Here's what that means for people who get generic ...

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

Up to a third of the weight lost while taking weight loss jabs such as Wegovy and Mounjaro includes muscle and bone mass.